Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT03004599
Other study ID # MH-P-002
Secondary ID
Status Terminated
Phase N/A
First received December 9, 2016
Last updated November 1, 2017
Start date November 2016
Est. completion date October 2017

Study information

Verified date November 2017
Source Medico's Hirata Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Safety and Efficacy of SYM-SV/DS-002 in Patients with Severe Aortic Stenosis


Description:

To evaluate the safety and efficacy of Transfemoral Transcatheter Aortic Valve Implantation using SYM-SV-002 Aortic Bioprosthesis and SYM-DS-002 Transfemoral Delivery System in patients presenting with symptomatic severe aortic stenosis and with difficulty to safely undergo conventional surgical aortic valve replacement (AVR)


Recruitment information / eligibility

Status Terminated
Enrollment 11
Est. completion date October 2017
Est. primary completion date October 2017
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria:

1. At least one cardiologist and one cardiac surgeon agree that it is difficult for the patient to receive a surgical procedure due to medical factors such that the subject has various comorbidities and he/she is more likely to die or suffer from severe diseases than to have significant improvements by a surgical procedure.

2. Subject has senile degenerative aortic valve stenosis with:

- mean gradient > 40 mmHg, or maximum jet velocity greater than 4.0 m/sec by either resting or dobutamine stress echocardiogram, or simultaneous pressure recordings at cardiac catheterization

- AND an initial aortic valve area of = 0.8 cm2 (or aortic valve area index = 0.5 cm2/m2) by resting echocardiogram or simultaneous pressure recordings at cardiac catheterization

3. Subject is symptomatic from his/her aortic valve stenosis (AS), as demonstrated by New York Heart Association (NYHA) Functional Class II or greater.

4. The subject has been informed of the nature of this trial, agrees to its provisions and has provided written informed consent as approved by the IRB of the respective clinical site.

5. The subject or the subject's legal representative agrees to visit the site where he/she receives index procedure for all required post-procedure follow-ups.

Exclusion Criteria:

1. Evidence of an acute myocardial infarction = 30 days (The procedure day is counted as day 0.) before the implant procedure

2. Any percutaneous coronary or peripheral interventional procedures, including placements of bare metal stents are performed within 30 days prior to the implant procedure, or any drug eluting stents are placed within 6 months (One month is counted as 30 days.) prior to the implant procedure

3. Untreated clinically significant coronary artery disease (CAD) requiring revascularization

4. Blood dyscrasias as defined:

leukopenia (WBC < 1,000/mm3), thrombocytopenia (platelet count <50,000 cells/mm3), history of bleeding diathesis or coagulopathy

5. Cardiogenic shock manifested by low cardiac output, vasopressor dependence, or mechanical hemodynamic support

6. Need for emergency surgery for any reason

7. Severe ventricular dysfunction with left ventricular ejection fraction (LVEF) < 20% as measured by resting echocardiogram

8. Cerebrovascular accident (CVA) or transient ischemic attack (TIA) within 6 months prior to the implant procedure (except mild TIA related to aortic stenosis)

9. End stage renal disease requiring chronic dialysis or serum creatinine > 3.0 mg/dL

10. Active Gastrointestinal (GI) bleeding within 3 months prior to the implant procedure

11. A known hypersensitivity or contraindication to any of the following which cannot be adequately pre-medicated:

- Aspirin

- Heparin (HIT/HITTS)

- Nitinol (titanium or nickel)

- P2Y12 inhibitors (such as Ticlopidine etc.)

- Contrast media

12. Ongoing sepsis, including active endocarditis

13. Subject refuses a blood transfusion

14. Life expectancy < 12 months due to associated non-cardiac comorbid conditions

15. Other medical, social, or psychological conditions that in the opinion of a principal investigator or sub-investigator precludes the subject from appropriate consent

16. Severe dementia (unable to provide informed consent for the treatment/procedure, unable to live an independent life outside of a chronic care facility, or expected to be fundamentally unable to undergo rehabilitation after the procedure, or unable to come to the site for follow-up visits)

17. Currently participating in other trials of investigational drugs or other investigational devices

18. Native aortic annulus size < 21 mm or > 27 mm per the baseline diagnostic imaging

19. Pre-existing prosthetic heart valve and / or prosthetic ring in any position

20. Mixed aortic valve disease (aortic stenosis and predominant aortic regurgitation (3-4+))

21. Moderate to severe (3-4+) or severe (4+) mitral regurgitation or severe (4+) tricuspid regurgitation

22. Moderate to severe mitral stenosis

23. Hypertrophic obstructive cardiomyopathy

24. New or untreated echocardiographic evidence of intracardiac mass, thrombus or vegetation

25. Congenital bicuspid or unicuspid valve verified by echocardiograph

26. Extreme eccentric calcification of the native aortic valve

27. Transesophageal echocardiogram (TEE) is contraindicated.

28. Scheduled surgical or percutaneous procedure to be performed prior to 1-month visit post-implant procedure

29. Hepatic failure (Child C or more)

30. Aortic or peripheral condition NOT appropriate for transfemoral implant due to the size, disease and degree of calcification or tortuosity of the aorta or ilio-femoral arteries

31. Thoracic or abdominal aortic aneurysm

32. Woman who is pregnant, breastfeeding or willing to become pregnant

Study Design


Intervention

Device:
SYM-SV-002 Aortic Bioprosthesis and SYM-DS-002 Transfemoral Delivery System
Transcatheter Aortic Valve Implantation via Transfemoral Approach

Locations

Country Name City State
Japan Sakakibara Heart Institute Fuchu Tokyo
Japan Teikyo University Hospital Itabashi Tokyo
Japan Kokura Memorial Hospital Kitakyushu Fukuoka
Japan Keio University Hospital Shinjuku Tokyo
Japan Osaka University Hospital Suita Osaka

Sponsors (1)

Lead Sponsor Collaborator
Medico's Hirata Inc.

Country where clinical trial is conducted

Japan, 

Outcome

Type Measure Description Time frame Safety issue
Primary Survival rate at 12 months post-procedure
Secondary Occurrence rates of MACCE MACCE is defined as a composite of:
All Cause Mortality
Myocardial infarction (MI)
All Stroke
Reintervention
at 1 month, 6 months, 12 months, 2 years, 3 years, 4 years and 5 years post-procedure
Secondary Occurrence rates of individual MACCE components Individual MACCE components include:
All Cause Mortality
Myocardial infarction (MI)
All Stroke
Reintervention
at 1 month, 6 months, 12 months, 2 years, 3 years, 4 years and 5 years post-procedure
Secondary Occurrence rates of Major Adverse Events (MAEs) MAEs include:
MACCE
Acute Kidney Injury (AKI)
Cardiac Tamponade
Prosthetic Valve Dysfunction (PVD)
Cardiogenic Shock
Prosthetic Valve Endocarditis
Life-Threatening, Disabling or Major Bleeding
Major Vascular Complications
Cardiac Perforation
Device Migration/Valve Embolism
at 1 month, 6 months, 12 months, 2 years, 3 years, 4 years and 5 years post-procedure
Secondary Occurrence rate of conduction disturbance requiring Permanent Pacemaker Implantation(PPI) at 1 month, 6 month, 12 months, 2 years, 3 years, 4 years and 5 years post-procedure
Secondary Change in NYHA class from baseline at 1 month, 6 months, 12 months, 2 years, 3 years, 4 years and 5 years post-procedure
Secondary Change in distance walked during 6-Minute Walk Test (6MWT) from baseline at 1 month and 12 month post-procedure
Secondary Change in QOL from baseline Kansas City Cardiomyopathy Questionnaire (KCCQ) at 1 month, 6 months, 12 months, 2 years, 3 years, 4 years and 5 years post-procedure
Secondary Change in QOL from baseline SF-36 at 1 month, 6 months, 12 months, 2 years, 3 years, 4 years and 5 years post-procedure
Secondary Echocardiographic assessment of valve performance Effective Orifice Area Index (EOAI) at 1 month, 6 months, 12 months, 2 years, 3 years, 4 years and 5 years post-procedure
Secondary Echocardiographic assessment of valve performance Mean gradient at 1 month, 6 months, 12 months, 2 years, 3 years, 4 years and 5 years post-procedure
Secondary Echocardiographic assessment of valve performance Degree of Aortic valve Regurgitation (AR) (Transvalvular and Paravalvular) at 1 month, 6 months, 12 months, 2 years, 3 years, 4 years and 5 years post-procedure
Secondary Echocardiographic assessment of valve performance Left ventricular ejection fraction (LVEF) at 1 month, 6 months, 12 months, 2 years, 3 years, 4 years and 5 years post-procedure
Secondary Device success Device success is defined as that all of the following are achieved:
Successful vascular access
Successful delivery and deployment of the device
Successful retrieval of the delivery system
Correct position of the device in the proper anatomical location (placement in the aortic annulus with no impedance on device function)
Intended performance of the prosthetic heart valve is confirmed by echocardiography (defined as below):
No Patient-Prosthesis Mismatch (PPM) (EOAI >0.85cm2/m2)
And mean aortic valve gradient < 20 mmHg or peak velocity < 3 m/sec,
And no moderate or severe prosthetic valve regurgitation
Only one valve implanted in the proper anatomical location
Number of days from admission to discharge (estimated to be at 7 days post-procedure on average)
Secondary Procedural success Procedural success is defined as that all of the following are achieved:
Achievement of the device success
Absence of in-hospital MACCE
Number of days from admission to discharge (estimated to be at 7 days post-procedure on average)
Secondary Occurrence rate of Prosthetic Valve Dysfunction (PVD) Prosthetic Valve Dysfunction (PVD) is defined as:
Aortic regurgitation (AR) reported as moderate or severe by echocardiography assessments
Significant aortic stenosis (AS) which meets one or more of the following by echocardiography assessments:
Peak velocity > 4 m/s
Mean gradient > 35 mmHg
Effective Orifice Area (EOA) < 0.8 cm2
TVIV1/TVIV2 < 0.25
at 1 month, 6 months, 12 months, 2 years, 3 years, 4 years and 5 years post-procedure
Secondary Occurrence rate of clinical endpoints per VARC 2 Mortality
Stroke
Myocardial infarction (MI)
Bleeding complications
Acute kidney injury (AKI)
Vascular complications
Conduction disturbances and arrhythmia
Other TAVI-related complications
at 1 month post-procedure
See also
  Status Clinical Trial Phase
Completed NCT01238497 - SOURCE XT REGISTRY
Recruiting NCT04029844 - Colibri Transcatheter Aortic Heart Valve System Study N/A
Recruiting NCT03280433 - Influence of EPICardial Adipose Tissue in HEART Diseases: EPICHEART Study N/A
Completed NCT05492383 - SAvvyWireâ„¢ EFficacy and SafEty in Transcatheter Aortic Valve Implantation Procedures (SAFE-TAVI) N/A
Active, not recruiting NCT03752866 - The CONFIDENCE Registry N/A
Completed NCT01651780 - Open-label, Randomized Trial in Patients Undergoing TAVR to Determine Safety & Efficacy of Bivalirudin vs UFH Phase 3
Recruiting NCT06173115 - Comparison of a Single Versus Double Perclose Technique for TAVR N/A
Recruiting NCT06136429 - A Prospective, Multicenter, Single-arm Study to Evaluate a Transcatheter Aortic Valve System Safety and Efficacy for the Treatment of Patients With Severe Aortic Stenosis N/A
Not yet recruiting NCT06015997 - Prevalence of ATTR Cardiac Amyloidosis in Patients Undergoing TAVR
Recruiting NCT03291925 - Primary Non-invasive Cardiac Computed Tomography Versus Routine Invasive Angiography Prior to TAVI N/A
Recruiting NCT04076150 - Safety and Performance Study of the Optimum Transcatheter Aortic Valve N/A
Completed NCT01074658 - CoreValve Advance International Post Market Study N/A
Completed NCT02575768 - Myocardial Flow Reserve in Severe AS Without Obstructive Coronary Artery Disease N/A
Completed NCT01994330 - Severe Aortic Stenosis and Acquired Von Willebrand´s Disease: The Impact of Desmopressin in Valve-Replacement Surgery Phase 4
Completed NCT04286893 - Improved HRV, Inflammation Markers and Endothelial Function After TAVI
Not yet recruiting NCT06177392 - VARC-TAVI VALVE IMPLANTATION) N/A
Active, not recruiting NCT04206228 - Intravenous Iron Supplement for Iron Deficiency in Patients With Severe Aortic Stenosis Phase 2
Not yet recruiting NCT03788590 - Evaluate the Transcatheter Artificial Aortic Valve and Transcatheter Artificial Heart Values Delivery System N/A
Completed NCT01531374 - Safety and Efficacy Continued Access Study of the Medtronic CoreValve® System in the Treatment of Symptomatic Severe Aortic Stenosis in Very High Risk Subjects and High Risk Subjects Who Need Aortic Valve Replacement N/A
Recruiting NCT05493657 - Aspirin vs Clopidogrel After TAVR N/A